Compare DexCom, Inc. (DXCM) vs Vistra Corp (VST) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Vistra Corp. (VST) trades at $152.50, down 3.74% amid broader market volatility, but maintains strong analyst support with a 90.91% buy rating. The stock shows bullish technical signals with support at $148 and resistance at $165, while fundamentals reveal robust profitability with 11.52% net income margin and 74.92% ROE. Recent earnings beat expectations in Q1 2026, and the company benefits from long-term power purchase agreements with major tech firms.

Outlook remains positive given Vistra's strategic focus on renewables and AI-driven power demand, though investors face risks from power-price volatility and high debt. The consensus price target of $253.00 implies significant upside potential, supported by institutional confidence and resilient cash flow trends.